Isozaki, Hideko http://orcid.org/0000-0003-0124-996X
Sakhtemani, Ramin http://orcid.org/0000-0001-5342-9415
Abbasi, Ammal
Nikpour, Naveed
Stanzione, Marcello
Oh, Sunwoo http://orcid.org/0000-0001-9205-4660
Langenbucher, Adam
Monroe, Susanna http://orcid.org/0000-0002-4775-4323
Su, Wenjia
Cabanos, Heidie Frisco
Siddiqui, Faria M.
Phan, Nicole
Jalili, Pégah
Timonina, Daria
Bilton, Samantha
Gomez-Caraballo, Maria
Archibald, Hannah L.
Nangia, Varuna http://orcid.org/0000-0001-5142-4653
Dionne, Kristin
Riley, Amanda http://orcid.org/0000-0002-5720-3269
Lawlor, Matthew
Banwait, Mandeep Kaur
Cobb, Rosemary G.
Zou, Lee http://orcid.org/0000-0003-3094-1058
Dyson, Nicholas J.
Ott, Christopher J. http://orcid.org/0000-0001-6142-7241
Benes, Cyril http://orcid.org/0000-0002-8751-9707
Getz, Gad
Chan, Chang S. http://orcid.org/0000-0001-9897-4759
Shaw, Alice T. http://orcid.org/0000-0001-6337-1093
Gainor, Justin F.
Lin, Jessica J. http://orcid.org/0000-0001-7373-3916
Sequist, Lecia V. http://orcid.org/0000-0002-8965-6991
Piotrowska, Zofia
Yeap, Beow Y.
Engelman, Jeffrey A.
Lee, Jake June-Koo http://orcid.org/0000-0003-1348-4094
Maruvka, Yosef E.
Buisson, Rémi http://orcid.org/0000-0002-7196-8209
Lawrence, Michael S. http://orcid.org/0000-0002-1307-459X
Hata, Aaron N. http://orcid.org/0000-0002-6127-318X
Article History
Received: 28 September 2020
Accepted: 8 June 2023
First Online: 5 July 2023
Competing interests
: A.N.H. has received grants/research support from Amgen, Blueprint Medicines, BridgeBio, Bristol-Myers Squibb, C4 Therapeutics, Eli Lilly, Novartis, Nuvalent, Pfizer, Roche/Genentech and Scorpion Therapeutics; and has served as a compensated consultant for Engine Biosciences, Nuvalent, Oncovalent, TigaTx and Tolremo Therapeutics. C.J.O. has received research support from Gilead, Scorpion Therapeutics and eFFECTOR Therapeutics. G.G. has received research funds from IBM and Pharmacyclics; is an inventor on patent applications related to MSMuTect, MSMutSig, MSIDetect, POLYSOLVER, SignatureAnalyzer-GPU and MinimuMM-seq; and is a founder, consultant and has privately held equity in Scorpion Therapeutics. J.F.G. has served as a compensated consultant and/or had advisory roles for Amgen, Blueprint Medicines Corporation, BMS, Genentech/Roche, Gilead Sciences, Jounce Therapeutics, Lilly, Loxo Oncology, Merck, Mirati, Silverback Therapeutics, Sanofi, GlydeBio, Moderna Therapeutics, Oncorus, Regeneron, Takeda, Merus, Novocure, Curie Therapeutics, AI Proteins, AstraZeneca, Jazz Pharmaceuticals, InterVenn and Pfizer; has stock and ownership in Ironwood Pharmaceuticals (immediate family member) and AI Proteins; has received Honoraria from Merck, Novartis, Pfizer and Takeda; has received research funding from Adaptimmune, ALX Oncology, Array BioPharma, AstraZeneca, Blueprint Medicines Corporation, BMS, Genentech, Jounce Therapeutics, Merck, Novartis and Tesaro; and has an immediate family member who is an employee of Ironwood Pharmaceuticals. J.J.L. has served as a compensated consultant or received honorarium from Chugai Pharma, Boehringer-Ingelheim, Pfizer, C4 Therapeutics, Nuvalent, Turning Point Therapeutics, Blueprint Medicines, Mirati Therapeutics, Novartis, Elevation Oncology, Bayer, Genentech and Regeneron; received institutional research funds from Hengrui Therapeutics, Turning Point Therapeutics, Neon Therapeutics, Relay Therapeutics, Roche/Genentech, Pfizer, Linnaeus Therapeutics, Elevation Oncology, Nuvalent and Novartis; and received travel support from Pfizer. L.V.S. has served as a compensated consultant for Genentech, AstraZeneca and Janssen, and has received institutional research support from BI, AZ, Novartis, Genentech, LOXO and Blueprint Medicines. M.L. has served as a compensated consulted for C4 Therapeutics. R.B. has served as a compensated consultant for Pfizer and Health Advances. Y.E.M. has served as a compensated consultant for Foresee Genomics. Z.P. has served as a compensated consultant and/or received honoraria from Sanofi, Janssen, Taiho, Takeda, AstraZeneca, Eli Lilly, Daiichi Sankyo, Cullinan Oncology, C4 Therapeutics, Jazz Pharmaceuticals, Blueprint Medicines, InCyte and Genentech, travel support from AstraZeneca and research funding (to institution) from Novartis, Takeda, Spectrum, AstraZeneca, Tesaro/GSK, Cullinan, Daiichi Sankyo, AbbVie, Janssen and Blueprint. M.S. is currently an employee of ImmunoGen, C.B. and A.T.S. are currently employees of Novartis, Inc. and J.A.E. is currently an employee of Treeline Biosciences (their contributions to the manuscript occurred while they were employees of Massachusetts General Hospital). The remaining authors declare no competing interests.